NFKB2 and neoplasm: We further confirmed the p52-driven tumorigenic effects in vivo whereby TWEAK overexpression significantly increased the growth of U-87 MG tumour xenografts, but this was reduced by CRISPR/Cas9-mediated knockdown of NFKB2 or ETS1 (Fig. 3c, d, Supplementary Fig. 5).